| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
|
JAMA
|
2011
|
7.61
|
|
2
|
Marital status and survival in patients with cancer.
|
J Clin Oncol
|
2013
|
5.82
|
|
3
|
Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
|
J Clin Oncol
|
2011
|
4.60
|
|
4
|
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery.
|
J Clin Oncol
|
2012
|
2.85
|
|
5
|
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy.
|
Brachytherapy
|
2012
|
2.05
|
|
6
|
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
|
Urology
|
2013
|
2.04
|
|
7
|
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy.
|
Urology
|
2010
|
1.83
|
|
8
|
Barriers to the implementation of surveillance for stage I testicular seminoma.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.58
|
|
9
|
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.55
|
|
10
|
Improvement in prostate cancer survival over time: a 20-year analysis.
|
Cancer J
|
2012
|
1.47
|
|
11
|
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.44
|
|
12
|
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period.
|
Cancer
|
2014
|
1.41
|
|
13
|
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.
|
J Oncol Pract
|
2013
|
1.05
|
|
14
|
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.04
|
|
15
|
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
|
BJU Int
|
2011
|
1.03
|
|
16
|
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.00
|
|
17
|
Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women.
|
Cancer
|
2011
|
0.97
|
|
18
|
Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.
|
Cancer
|
2013
|
0.95
|
|
19
|
Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients.
|
Ann Surg Oncol
|
2013
|
0.94
|
|
20
|
Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.94
|
|
21
|
External-beam accelerated partial breast irradiation using multiple proton beam configurations.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.93
|
|
22
|
Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.93
|
|
23
|
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.93
|
|
24
|
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.89
|
|
25
|
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.86
|
|
26
|
Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment.
|
Cancer
|
2014
|
0.86
|
|
27
|
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control.
|
Breast Cancer Res Treat
|
2011
|
0.85
|
|
28
|
Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications.
|
Med Care
|
2016
|
0.84
|
|
29
|
Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a Surveillance, Epidemiology, and End Results Patterns-of-Care Study.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
30
|
Management of prostate cancer in elderly men.
|
Semin Radiat Oncol
|
2013
|
0.83
|
|
31
|
Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?
|
Eur J Cancer
|
2012
|
0.81
|
|
32
|
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.
|
Ann Surg Oncol
|
2011
|
0.79
|
|
33
|
Development of a standard survivorship care plan template for radiation oncologists.
|
Pract Radiat Oncol
|
2015
|
0.78
|
|
34
|
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.
|
Cancer
|
2010
|
0.78
|
|
35
|
Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.78
|
|
36
|
Radiation therapy modalities in prostate cancer.
|
J Natl Compr Canc Netw
|
2013
|
0.76
|
|
37
|
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.
|
Ann Surg Oncol
|
2013
|
0.76
|
|
38
|
Emergence of integrated urology-radiation oncology practices in the State of Texas.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.75
|
|
39
|
The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer.
|
Am J Clin Oncol
|
2016
|
0.75
|
|
40
|
Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.
|
Brachytherapy
|
2013
|
0.75
|